| Value | ₹1.56 Cr |
|---|
NSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹143.10
- Market cap
- ₹767.9 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 207.8×Sector 46.5×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Other acquisition announcements
All →Emkay Global Financial Services Acquisition Worth ₹21.38 Cr
Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.
- Value
- ₹21.38 Cr
- Execution
- 90 days
TVS Motor Company Acquisition Worth ₹25,000 Cr
TVS Motor will acquire 100% of Harita ARC Limited, a related-party shell, for a stated Rs 25,000 Crore. It supports the proposed consumer finance demerger.
- Value
- ₹25,000 Cr
Rite Zone Chemcon India Acquisition Worth ₹4.97 Cr
Rite Zone Chemcon's board approved acquiring 51% of Cleanux Green Solution via share swap for about INR 4.97 Crore. The board also approved preferential issues and an EGM on 23 November 2026.
- Value
- ₹4.97 Cr
eClerx Services Acquisition Worth ₹15.57 Cr
eClerx's board approved buying about 2% of Personiv Eclipse Inc. from its wholly owned subsidiary eClerx LLC for USD 1.64 million. The intra-group transfer adds no change to aggregate ownership.
- Value
- ₹15.57 Cr
- Execution
- 1 Month
Fortis Healthcare Acquisition Worth ₹277 Cr
Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.
- Value
- ₹277.0 Cr
Authum Investment & Infrastructure Acquisition
NCLT approved the consortium resolution plan for A A Estates Private Limited, with Authum as a resolution applicant. No consideration amount is disclosed.